TrialLeukemia research2018

Report of the relapsed/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML).

Anjali S Advani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.